ArticleScience China. Life sciences2025
(Z)-Ligustilide alleviates intervertebral disc degeneration by suppressing nucleus pulposus cell pyroptosis via Atg5/NLRP3 axis.
Article in Science China. Life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Ginsenoside Rh2 Attenuates Intervertebral Disc Degeneration by Modulating the PI3K/AKT Signaling Pathway to Suppress Apoptosis.International journal of molecular sciences · 2026Article
- Review
- Nrf2 Activators in Parkinson's Disease: Modulating Mitophagy and Regulating Cuproptosis.Molecular neurobiology · 2026Review
- Efficacy and Mechanisms of Duhuo Jisheng Decoction in Treating Intervertebral Disc Degeneration: A Network Pharmacology and Experimental Study.Current medical science · 2026Article
- Beyond the hype: the glycolysis-pyroptosis axis in intervertebral disc degeneration and the path to therapeutic translation.Apoptosis : an international journal on programmed cell death · 2026Article
- Establishment and research progress of animal models for intervertebral disc degeneration.Open life sciences · 2026Article
- Rebuilding the degenerative disc microenvironment: mesenchymal stem cells, exosomes, and bioengineered scaffolds.Frontiers in bioengineering and biotechnology · 2026Review
- Ligustilide: A Phytochemical with Potential in Combating Cancer Development and Progression-A Comprehensive and Critical Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IVDD) represents one of the most prevalent degenerative disorders, significantly impairing quality of life and overall health. The inflammatory cascade and dysregulated degradation of the extracellular matrix (ECM) triggered by pyroptosis are considered key mechanisms underlying the pathogenesis of IVDD. Research has highlighted the potential of Chuanxiong Rhizoma (CX), a traditional Chinese medicine, in exerting anti-pyroptotic effects; nevertheless, the exact mechanisms and pathways through which it modulates inflammation, as well as its potential role in the context of IVDD, remain unknown. Network pharmacology analysis was initially employed to identify the principal components and targets of Chuanxiong Rhizoma (CX) in the treatment of IVDD, ultimately selecting LIG as the key active ingredient responsible for its therapeutical effect. To explore the therapeutic effects of LIG on IVDD, we established a rat acupuncture model to simulate IVDD in vivo. Additionally, we used lipopolysaccharide (LPS) and adenosine triphosphate (ATP) to induce NPC degeneration model in vitro. In vitro experiments revealed that LIG treatment promotes the expression of anabolic markers such as Collagen II and Aggrecan while inhibiting the expression of catabolic markers MMP9 and MMP13 in nucleus pulposus cells (NPCs). Furthermore, LIG was also shown to inhibit cell pyroptosis and the secretion of inflammatory cytokines, which was mediated by NLRP3/caspase-1/GSDMD-N activation. Molecular docking and co-immunoprecipitation further demonstrated that LIG acts as a ligand for the Atg5 protein, inhibiting its degradation and promoting its interaction with the NLRP3 protein, ultimately leading to the suppression of pyroptosis activation in NPCs. It was also found that knocking down Atg5 reverses the protective effects of LIG and exacerbates pyroptosis-mediated inflammation in IVDD. In addition, in vivo experiments also showed that LIG delayed acupuncture-mediated IVDD development. Therefore, this paper confirmed that LIG has the ability to protect NPCs against pyroptosis through Atg5/NLRP3 axis and exert its therapeutic application to ameliorate disc degeneration in vivo. This may shed new insights into the role of LIG in IVDD treatment and offer a mechanistic basis for targeting NLRP3-mediated pyroptosis.
Indexed as
Identifiers
40614011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.